AlzeCure Pharma AB (publ) (STO:ALZCUR)

Sweden · Delayed Price · Currency is SEK

1.375

-0.005 (-0.36%)

Apr 29, 2026, 3:41 PM CET

-42.71% (1Y)

Market Cap	158.58M
Revenue (ttm)	n/a
Net Income (ttm)	-47.65M
Shares Out	114.91M
EPS (ttm)	-0.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,483
Average Volume	112,444
Open	1.380
Previous Close	1.380
Day's Range	1.360 - 1.380
52-Week Range	1.300 - 4.950
Beta	0.01
RSI	35.52
Earnings Date	Apr 8, 2026

About AlzeCure Pharma AB

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are i... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 10

Stock Exchange Nasdaq Stockholm

Ticker Symbol ALZCUR

Full Company Profile

Financial Performance

Financial Statements

News

AlzeCure Pharma AB Transcript: Status Update

Orphan drugs are a rapidly growing, high-value segment, driven by unmet needs and strong incentives. ACD 440, a topical TRPV1 antagonist, targets erythromelalgia—a rare, severe pain disorder—with promising clinical results and orphan designation, positioning it for out-licensing and global commercialization.

8 months ago - Transcripts

AlzeCure Pharma AB Transcript: Study Update

ACD440, a topical TRPV1 antagonist gel, has shown significant pain reduction and strong safety in phase Ib and IIa studies for neuropathic pain with thermal hypersensitivity. The product offers local, predictable relief, can be combined with other treatments, and targets a large, growing market with high unmet need.

1 year ago - Transcripts

AlzeCure Pharma AB Transcript: Status Update

2 years ago - Transcripts